Marinus Pharmaceuticals Stock Quote MRNS - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

1.70

Bid

1.67

Ask

1.73

Volume

1,323,595

1.55 Day's Range 1.68

1.05 52 Week Range 11.26

Market Cap

93.643M

Previous Close

1.60

Open

1.62

Last Trade

2000

1.7

(formt)

Last Trade Time

Financial Volume

$ 2,123,808

VWAP

1.6046

Average Volume (3m)

610,321

Shares Outstanding

55,084,038

Dividend Yield

PE Ratio

-0.64

Earnings Per Share (EPS)

-2.57

Revenue

30.99M

Net Profit

-141.41M

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychi... Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.marinuspharma.com

Headquarters

Wilmington, Delaware, USA

Founded

Marinus Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MRNS. The last closing price for Marinus Pharmaceuticals was $1.60. Over the last year, Marinus Pharmaceuticals shares have traded in a share price range of $ 1.05 to $ 11.26.

Marinus Pharmaceuticals currently has 55,084,038 shares outstanding. The market capitalization of Marinus Pharmaceuticals is $88.13 million. Marinus Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.64.

Form 8-K - Current report

Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day

Enrollment complete and on track to report topline data from the TrustTSC trial in tuberous sclerosis complex (TSC) in the first half of Q4 with NDA filing targeted for April 2025 TrustTSC...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.29	20.5673758865	1.41	1.73	1.4	589479	1.52883498	CS
4	0.36	26.8656716418	1.34	1.73	1.29	415332	1.45538147	CS
12	0.46	37.0967741935	1.24	1.73	1.05	610321	1.30994559	CS
26	-7.57	-81.6612729234	9.27	9.41	1.05	1382371	1.72168302	CS
52	-5.52	-76.4542936288	7.22	11.26	1.05	923734	3.38590292	CS
156	-10.12	-85.6175972927	11.82	13.15	1.05	599752	5.47814487	CS
260	0.33	24.0875912409	1.37	20.04	1	1014187	4.48686273	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BNZIBanzai International Inc	$ 5.645 (96.01%)	61.39M
ZJYLJin Medical International Ltd	$ 3.975 (50.00%)	1.24M
ANEBAnebulo Pharmaceuticals Inc	$ 2.9001 (39.43%)	78.85k
XPONExpion360 Inc	$ 0.081 (39.18%)	1.46B
AENTAlliance Entertainment Holding Corporation	$ 2.74 (34.31%)	4.23M
GSIWGarden Stage Ltd	$ 1.34 (-82.89%)	26.41M
CRBPCorbus Pharmaceuticals Holdings Inc	$ 19.51 (-62.26%)	12.29M
LGCBLinkage Global Inc	$ 0.4183 (-57.70%)	2.16M
BFIBurgerFi International Inc	$ 0.0855 (-42.27%)	15.04M
SKYESkye Bioscience Inc	$ 3.17 (-42.26%)	5.14M
XPONExpion360 Inc	$ 0.081 (39.18%)	1.46B
NVDANVIDIA Corporation	$ 116.00 (-1.59%)	378.15M
AAPLApple Inc	$ 228.20 (-0.29%)	320.24M
INTCIntel Corporation	$ 21.84 (3.31%)	261.64M
VERBVerb Technology Company Inc	$ 0.0742 (33.45%)	178.64M